|
Overview
The concept behind ABSPII is that capacity in
agricultural biotechnology can best be built through the careful
and studied delivery of selected bio-engineered products. Working
with actual products, the capacity of scientists, regulators,
extension workers, farmers and the general public to make informed
decisions will be improved. An important supporting result is
that improved products actually reach the farmers and contribute
to more productive agricultural systems that improve people’s
lives.
Identifying products that not only can be delivered in the 5-10
years of the project, but that also have a market and the potential
to provide a genuine improvement over existing products, requires
not just an analysis of the available technology opportunities,
but also an awareness of local needs. Thus, local involvement
in needs assessment has been an important aspect of the priority
setting activities undertaken by ABSPII in this first year.
Recognizing that the diverse countries where ABSPII is mandated
to work exemplify very different stages in the involvement of
biotechnology in agriculture, products at various levels of development
needed to be identified in order to make certain that appropriate
expertise is developed in the future. In countries where bio-engineered
crops are already approved and experience exists, the emphasis
will be on the commercial delivery of a product. In other countries
that do not yet have this capacity, sourcing existing products
for field trials and strengthening product development expertise
will be more important.
Priority Setting
Process
Workshop Process in Asia
Information on crop production constraints
and opportunities for bio-engineered products in Asia was collected
at ABSPII-organized workshops held in the Philippines, India,
Bangladesh and Indonesia. Participants were invited from the
country and region, with the aim of ranking potential products
and the identification of local implementing partners.
Bangladesh
Priority Setting Workshop Report
India
Priority Setting Workshop Report
Indonesia
Priority Setting Workshop Report
Philippine
Priority Setting Workshop Report
After the workshops, further information was solicited from
developers of specific products related to the following issues:
- Whether field trials have taken place or when they are
planned
- The freedom-to-operate status of the product and whether
any analysis has been done
- Components in the transgene
and whether any biosafety assessments have been carried
out on these components
- Value of the crop and the effect of
the constraint on production value
- Effect of the technology
in addressing the constraint
- Consideration of the potential
acceptance by local and international consumers
- Whether
the product might have an impact in other countries
in the region, or other regions
- Whether the product would be
particularly suited to poor farmers or disadvantaged
groups
In selected cases, an external review of the product was commissioned
in order to understand fully the status of the product.
Process in Africa
Process in East and Central Africa
A process for identification of regional
agricultural needs in East and Central Africa had been established
by the Association
for Strengthening Agricultural Research in Central
and Eastern Africa (ASARECA). USAID
has been supporting the establishment of a biotechnology
network within ASARECA as an aid in the development
of capacity within the region.
ABSPII has been involved in the formal priority setting
process employed for the entire ASARECA network but, as
there were
a number of different aims of this process, the outcomes
were not applicable directly to ABSPII. ABSPII is focused
on bio-engineered
products, but ASARECA’s biotechnology initiative considered
a broader range of activities including tissue culture, marker
assisted selection, animal vaccine development and micro propagation.
Similarly, because ASARECA consists of a set of commodity networks
created a number of years ago to provide a mechanism for regional
implementation, some crops are not covered. Some very promising
potential products thus fall outside of ASARECA’s
current remit and additional partners are needed. Other
consortium
partners in Africa, including international research
centers with activities in the region, have been involved
in the
identification process.
Further information was solicited from developers of specific
products related to the following issues:
- Whether field trials have taken place or when they are planned
- The freedom-to-operate status of the product and whether
any analysis has been done
- Components in the transgene and whether any biosafety assessments
have been carried out on these components
- Value of the crop and the effect of the constraint on production
value
- Effect of the technology in addressing the constraint
- Consideration of the potential acceptance by local and international
consumers
- Whether the product might have an impact in other countries
in the region, or other regions
- Whether the product would be particularly suited to poor
farmers or disadvantaged groups
In selected cases, an external review of the product was commissioned
in order to understand fully the status of the product.
As the number of potential products was somewhat less,
the fact that products had the potential to be developed
to the
stage of field trials was significant.
Process in West Africa
Le Conseil Ouest et Centre
Africain pour la Recherche et le Développement Agricoles (CORAF)
is a central part of the ABSPII strategy in West Africa.
Support to develop CORAF’s biotechnology activities
is a role for which ABSPII and its product-focused approach
are well
suited. However, as there are no priority setting activities
upon which ABSPII can draw, more reliance has been
placed on existing and commissioned reports to identify
needs.
Potential
products have been identified by regional partners
and other consortium members as well as through discussions
with USAID
missions in the region.
Further information was solicited from developers of specific
products related to the following issues:
- Whether field trials have taken place or when they are planned
- The freedom-to-operate status of the product and whether
any analysis has been done
- Components in the transgene and whether any biosafety assessments
have been carried out on these components
- Value of the crop and the effect of the constraint on production
value
- Effect of the technology in addressing the constraint
- Consideration of the potential acceptance by local and international
consumers
- Whether the product might have an impact in other countries
in the region, or other regions
- Whether the product would be particularly suited to poor
farmers or disadvantaged groups
In selected cases, an external review of the product was commissioned
in order to understand fully the status of the product.
Since there were few potential products, the fact that they
had the potential to be developed to the stage of field trials
was
significant.
SWOT Analysis
An analysis of the strengths, weaknesses, opportunities
and threats for each candidate product commercialization package
was undertaken. Information was obtained either directly from
the developer or internally by the ABSPII management team, to
identify critical information needed in this respect related
to each potential product.
|